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EDITORIAL
Nephritogenic immunopathologic mechanisms and human
renal transplants: The problem of recurrent
glomerulonephritis
Several factors, including widespread clinical renal
transplantation, histopathologic recognition of gb-
merular disease within grafts [1—4] and elucidation
of the principal immunopathogenetic mechanisms
causative of glomerulonephritis in experimental ani-
mals and human renal disease [5], have combined to
cause keen awareness of the potential risks of recur-
rent glomerulonephritis in renal grafts. This aware-
ness has been strengthened by reported experience
with renal isografts in which most patients whose
underlying disease was glomerulonephritis developed
glomerulonephritis in their grafts, ultimately causing
death in six of the 12 patients affected [6]. Moreover,
reports based on immunologic data indicated that
pathogenetic autoimmune mechanisms persisting in
the host could have important clinical expression in
patients with renal albografts, despite immunosup-
pressive therapy [7].
Nevertheless, the frequency of recurrent glomer-
ulonephritis, its histopathobogic characteristics and
clinical importance have not been established clearly.
Indeed, the frequency of glomerular disease in long-
surviving renal allografts, particularly in recipients
whose native kidney disease necessitating renal trans-
plantation apparently was not mediated immunolog-
ically, has caused some to question the relevance of
classic immunopathologic nephritogenic mechanisms
to these graft glomerulopathies [3, 4, 8].
In general, glomerulonephritis may occur in a renal
graft in one of three ways: a) as a result of a per-
sistently active nephritogenic mechanism responsible
for underlying disease in the recipient's native kid-
neys, b) by elicitation of an effective immunopathoge-
netic mechanism by the allograft (specific allograft
immunity) and c) de novo glomerulonephritis not due
to alloantibodies.
In the first instance, persistent glomerulonephritis
will be caused by antibodies with specificity for in-
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trinsic structural antigens associated with the gb-
merular basement membranes (GBM antibody dis-
ease) or by soluble, circulating, macromolecular
antigen-antibody complexes (immune-complex dis-
ease). These mechanisms are recognized presump-
tively by characteristic imm unohistochemical stain-
ing patterns for host immunogbobulins (Ig), and can
be confirmed by antibody elution studies in the case
of GBM antibody disease; in immune-complex dis-
ease the mechanism may be reconstructed by antigen
identification in the deposits or demonstration of spe-
cificity of eluted antibodies for non-GBM antigens.
In contrast, specific allograft immunity causing
glomerubonephritis requires either that soluble anti-
gens be released into the circulation to combine with
alloantibodies and induce immune-complex deposits
in graft gbomeruli, or that alloantibodies fix in situ
with soluble, membrane-associated antigens (for ex-
ample, GBM).
De novo gbomerubonephritis may be caused by
autoimmune nephritogenic mechanisms related or
unrelated to the graft: acute poststreptococcal gb-
merubonephritis affecting a graft would be the proto-
type of de novo glomerulonephritis etiobogically un-
related to the graft, whereas induction of autologous
immune-complex disease might be considered proto-
typic of graft-related, organ-specific, but not allo-
specific, de novo glomerubonephritis [9—11].
Reports of histopathobogic and immunologic eval-
uation of renal graft specimens comprise three gen-
eral categories: detailed description of pathologic
specimens, reports of apparent recurrent disease in
renal albografts, and systematic studies of native kid-
neys and renal grafts from the same patients, with
emphasis on immunologic studies attempting to de-
fine the apparent nephritogenic mechanisms oper-
ational prior to graft placement. Several immuno-
histopathologic and ultrastructural investigations of
renal allografts have been very informative regarding
long-term gbomerular changes in surviving grafts;
these have been reviewed in detail by Mathew et al
[3], Olsen, Bohman and Petersen [4] and Porter [12].
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However, all investigators have stressed the poly-
morphic variations within individual kidneys, and the
difficulties imposed on such evaluations by ischemic
events, allograft rejection activity and other compli-
cations frequent in transplant recipients.
Rowlands et al [13], and Seigler et al [14], have
reported clinical, morphologic and immunohistoche-
mical data on series of renal allografts performed in
recipients closely matched to their donors at the ma-
jor HL-A loci (HL-A identical siblings), and whose
native kidneys also had been systematically examined
by morphologic and immunofluorescent tests. These
investigators judged that recurrent disease could be
diagnosed in two of 16 patients, with graft loss due to
glomerulonephritis in one recipient.
Stronger data regarding apparently persistent im-
munopathogenetic mechanisms affecting renal allo-
grafts are available from transplantation experience
at Wilford Hall USAF Medical Center [15]. Direct
immunofluorescent tests have been performed on na-
tive kidneys and renal allografts of 37 patients receiv-
ing 43 allografts; additionally, elutions have been
performed from 39 whole kidneys or open biopsies in
this group. Prospective recipients coming to renal
transplantation with significant immunoglobulin de-
posits on glomeruli of native kidneys (Ig-positive
group) developed graft glomerular Ig deposits in 16
of 20 patients, whereas graft glornerular Ig deposits
developed in only three of 17 patients whose native
kidneys were Ig-negative. Moreover, nine of these
patients developed linear deposits of lgG diffusely on
allograft glomeruli, presumptive of anti-GBM an-
tibody fixation in vivo. Elutions were performed on
native kidney tissue from all, and were positive in
eight of the nine cases, confirming that GBM an-
tibody activity involved native kidneys of these
patients and antedated renal allograft placement. The
sensitive radioimmunoassay of Wilson, Marquardt
and Dixon [16] was instrumental in detection of cir-
culating anti-GBM antibodies in the same eight
patients prior to grafting.
In contrast, clinical recurrence of glomerulone-
phritis was detected in only five patients in this same
group of Wilford Hall allograft recipients: one of
these had recurrent immune-complex glomerulo-
nephritis and four had anti-GBM antibody-mediated
disease. Whereas the first (recipient of allograft from
an HL-A identical sibling) has had relatively indolent
but progressive proliferative glomerulonephritis, the
latter four had onset of heavy, nephrotic range pro-
teinuria with urinary red blood cell casts within the
first seven to ten days following transplantation. Nev-
ertheless, in only one of the four was graft loss di-
rectly attributable to the recurrent glomerulone-
phritis. A sixth Wilford Hall patient with nephrotic
syndrome and Ig-negative, focal sclerosing glomeru-
lopathy in her native kidney has developed nephrotic
syndrome immediately upon diuresis from acute
tubular necrosis after transplantation of two succes-
sive renal allografts, associated with the recurrent, Ig-
negative, morphologic glomerular lesion. Immuno-
logic studies including serum transfer into primates
and elutions of native and graft kidneys have not
indicated a detectable immune mechanism in this
worn an.
Differences in incidences of recurrent disease re-
ported in different series are probably more apparent
than real, reflecting differences in sample size, selec-
tion of patients for transplantation, population dif-
ferences, varying etiologies of native kidney disease
from group to group and criteria for diagnosing re-
current glornerulonephritis. Based on the single crite-
rion of comparable histopathologic characteristics in
both native kidneys and allograft, estimates of recur-
rent disease range from 5 to 18% [3,4, 13, 14, 17, 18].
Data from Wilford Hall experience suggest a much
higher incidence of persistently active, nephritogenic
mechanisms in allograft recipients; nevertheless, clin-
ically and histologically identifiable, recurrent glomer-
ulonephritis falls within the estimates offered by
others.
There is a distinct hazard in the use of morphologic
criteria only for establishing the diagnosis of recur-
rent disease, and this hazard is well established exper-
imentally as well as in clinical nephritologic practice.
In experimental nephrotoxic glomerulonephritis, his-
tologic responses of the host and protein uria are de-
pendent on the amount of nephrotoxic antibody ad-
ministered acutely. Similarly, experiments conducted
with a single antigen, bovine serum albumin (BSA),
have demonstrated the wide range of morphologic
glomerular responses which occur in laboratory ani-
mals, dependent on the magnitude of antibody re-
sponse mounted by the host, relative equivalence of
antigen and antibody in the circulation and duration
of experimental protocols [19]. Experiments by Ger-
muth et al have confirmed these observations; more-
over, the efficacy of immunosuppressant steroids in
altering antibody synthesis in the face of constant
antigen load had clear impact on the localization of
immune complexes in the BSA—anti--BSA immune-
complex model, with resulting differences in the func-
tional and histologic expression of glomerular disease
in these rabbits [20].
In the course of clinical renal disease associated
with systemic lupus erythematosus, progression from
focal and mesangial to diffuse proliferative glomer-
ulonephritis has been reported [21] in several
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patients. In another particularly well-documented in-
stance [22], a young woman with apparently stable
idiopathic membranoproli ferative glomerulonephri-
tis developed generalized crescentic morphologic
changes after cessation of steroid and immunosup-
pressive therapy in both the native kidney and the
renal allograft. Moreover, renal functional deteriora-
tion after cessation of long-term prednisone and
azathioprine treatment has been suggested by Levitt
in three patients with primary renal disease [23].
These observations of apparent change of morpho-
logic lesion and clinical course imply that histopatho-
logic injury and morphology may vary with time, or
from native kidney to graft, in the face of persistently
effective immunopathogenetic mechanisms which
change in tempo and intensity, or are influenced by
immunosuppressant therapeutic programs.
A further dimension of the shortcoming of diag-
nosis by morphologic and immunohistochemical cri-
teria alone is emphasized clearly in immune-complex
renal disease. Histopathologic diagnosis of the latter
is inferred from tissue localization of electron-dense
deposits in mesagium or along GBM, associated with
a compatible localization of host immunoglobulins.
In the absence, however, of antigen identification,
there can be no certainty that immune deposits seen
at one point in time have the same antigenic composi-
tion at another.
Recent elucidation of the principle of secondary
disease has obvious relevance to a keener inter-
pretation of recurrent glomeruloneph ntis and poten-
tially also to ultimate prognosis: Kiassen et al de-
scribed in detail a patient with typical membranous
nephropathy who developed superimposed anti-GBM
glomerulonephnitis [24]. In addition, we have studied
a woman with a form of familial polycystic kid-
ney disease whose remaining normal glomeruli prior
to transplantation had linear deposits of Ig and
elutable GBM antibodies; an allograft placed into the
same woman also developed linear Ig deposition.
Milgrom, Klassen and Fuji have reviewed their own
experiments and pointed out the several ways that
humoral, antibody-mediated mechanisms may injure
a graft in the absence of direct, allospecific immunity
[11].
In addition to the foregoing considerations, renal
transplantation recipients are at risk for development
of infectious hepatitis, cytomegalovirus infections
and a number of superimposed infectious complica-
tions [25]. Such viral and bacterial antigens eliciting
humora! antibodies are capable of inducing immune-
complex disease and glomerular disease of grafted
kidneys. The frequency of these problems will vary
from one institution to another, but must be consid-
ered in addressing the nature, composition and spe-
cificities of immunoglobulin deposits in renal grafts.
Studies using partial elution of biopsy sections with
acid buffers and chaotropic media have not identified
hepatitis B surface antigen or renal tubular epithelial
antigen among allograft immune deposits detected at
Wilford Hall.
Demonstration of alloantigens in glomerular im-
mune deposits and/or specific concentration of al-
loantibodies in Ig eluted from allograft glomeruli will
provide the most convincing evidence that glomeru-
lar Ig deposits are attributable directly to any extent
to allospecific immunity. A more inferential and ob-
lique corollary to such demonstrations may utilize a
systematic study for circulating immune complexes
or cryoprecipitates in transplant recipients to detect
circulating, complexed alloantigens. Such data are
not available at the present time.
A significant variable whose importance cannot be
assessed directly in addressing the more limited field
of recurrent glomerulonephritis is immunosuppres-
sive drug therapy. If clinical renal isograft experience
is to be interpreted literally, persistent nephritogenic
mechanisms and recurrent glomerulonephritis should
emerge as an important and conspicuous threat to
technically successful, accepted grafts. Despite evi-
dence suggesting frequent persistence of active ne-
phritogenic mechanisms, the relatively low incidence
of clinically and histopathologically recognizable re-
current glomerulonephritis implies that immunosup-
pressive drug programs have some efficacy in restraint
and/or modification of ongoing nephritogenic proc-
esses not demonstrated yet in treatment of native
kidney diseases.
Nonetheless, it is a matter of record that certain
morphologically distinct diseases have an evident
propensity for recurrence after renal transplantation.
Foremost among these appear to be membranoprolif-
erative glomerulonephritis, particularly the dense in-
tramembranous deposit variant [26], lgA-associated
glomerulonephropathy [27], GBM antibody disease
[7, 15] and focal scierosing glomerulopathy [18], al-
though membranous nephropathy, lupus glomerulo-
nephritis and familial nephropathy also have been
observed.
We have not dealt in detail in these discussions
with specific renal disease entities or their recur-
rences, because it has been our purpose to emphasize
certain principles and recent data which concern the
general problem of recurrent glomerulonephritis. Ex-
tensive experimental immunopathology and well-
documented studies of human renal transplantations
attest to the validity of these principles and the real
risk to some grafts. Our present inability to predict
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precisely the certainty of recurrent clinical disease
precludes confident, arbitrary prohibitions about the
suitability of potential recipients, acceptable risks
and possible organ wastage. As others have pointed
out [8], accumulated experiences with renal trans-
plantation have emphasized several apparent enig-
mas in present nephrology. including the morpho-
logic and immunopathogenetic variants of mem-
branoproliferative glomerulonephritis, focal scieros-
ing glomerulopathy and glomerular diseases in grafts.
Continued, systematic and innovative use of experi-
mental and laboratory techniques is necessary in the
study of these problems so that we may establish
ultimately the interrelationships and quantitative im-
portance of contributory variables to operative hu-
moral mechanisms.
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